CONTINEUM THERAPEUTICS INC CLASS A (CTNM)
Health Care · Clinical-stage biopharmaceutical / small-molecule therapeutics · NASDAQ
A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for depression and multiple sclerosis.
What CONTINEUM THERAPEUTICS INC CLASS A does
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule drug candidates for neuroimmune and inflammatory (NI&I) indications with significant unmet medical need. The company is advancing two clinical-stage programs: PIPE-791, a brain-penetrant LPA1R antagonist for idiopathic pulmonary fibrosis and chronic pain; and PIPE-307, a selective M1R inhibitor partnered with Johnson & Johnson for depression and relapse-remitting multiple sclerosis. The company leverages its expertise in medicinal chemistry, biology, and clinical development to target clinically validated biological pathways.
Themes: []
Fundamentals
- Price$15.45 as of 2026-07-09 close
- Market cap$585M as of 2026-07-10
- 1-year return+299.2% as of 2026-07-09 close
- Net margin+45.4% as of 2026-07-10
- ROE-27.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.55 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.